Alteogen's Novel Biosimilar EYLUXVI® Secures European Commission Approval Alteogen Inc. celebrates EC approval for EYLUXVI®, expanding its biosimilar portfolio. This new formulation targets critical ophthalmic conditions and enhances availability.

Alteogen's Novel Biosimilar EYLUXVI® Secures European Commission Approval #South_Korea #Daejeon #Biosimilar #EYLUXVI #Alteogen

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion Alteogen's EYLUXVI®, an aflibercept biosimilar, receives a positive opinion from CHMP, paving the way for improved treatment of age-related macular degeneration.

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion #South_Korea #Daejeon #Aflibercept #EYLUXVI #Alteogen